Influenza A virus H1N1 antigens (H1N1)

Influenza A virus H1N1 antigens are a group of essential proteins located on the surface of the H1N1 influenza virus that facilitate host infection and serve as the primary targets for the immune system and pharmacological interventions. The two most prominent antigens are Hemagglutinin (HA), which mediates viral attachment to sialic acid receptors on respiratory cells and subsequent membrane fusion, and Neuraminidase (NA), an enzyme that cleaves sialic acid to release newly formed progeny virions from the host cell. A third critical antigen, the Matrix protein 2 (M2), acts as a proton-selective ion channel required for viral uncoating within the endosome. These proteins are the focus of therapeutic strategies, including vaccines that induce neutralizing antibodies and antiviral drugs that inhibit specific viral functions. However, the high mutation rate of these antigens through processes like antigenic drift and shift frequently leads to the emergence of drug-resistant strains and necessitates the periodic updating of vaccine compositions.

Other names

H1N1 surface proteinsInfluenza A virus subtype H1N1 antigensSwine flu antigensA(H1N1) antigensH1N1 glycoproteins

Neuraminidase inhibitors (e.g., oseltamivir) prevent the release of progeny virions from the host cell surface by blocking the enzymatic cleavage of sialic acid; M2 proton channel inhibitors (e.g., amantadine) block the acidification of the virion to prevent viral uncoating; hemagglutinin-targeted interventions (e.g., vaccines, monoclonal antibodies) inhibit viral attachment to host cells or prevent membrane fusion.